Naflox

Quick links to important sections

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Naflox

What is Naflox? (Overview and Quick Facts)

Property Description
Active Ingredient Norfloxacin
Form Tablet (Oral), Ophthalmic Solution (Eye Drops)
Pharmacological Class Fluoroquinolone Antibiotic
General Purpose Anti-infective agent against susceptible bacteria
Origin Synthetic, quinolone carboxylic acid derivative

What Type of Medicine is Naflox? (Classification and Identity)

Naflox is a prescription-only medication containing the active ingredient Norfloxacin, which is formally classified as a fluoroquinolone antibiotic. This compound is a chemically engineered quinolone carboxylic acid derivative, distinguishing its synthetic origin from naturally occurring antibiotics. Pharmacological studies clinically recognize Norfloxacin's efficacy as a first-generation fluoroquinolone agent. This classification means Norfloxacin was among the earliest synthetic quinolones developed for systemic use, known for its specific targeting of gram-negative bacteria.

Naflox Forms: Tablets vs. Ophthalmic Solution

Naflox is supplied as a single-ingredient product in two distinct pharmaceutical preparations: the film-coated tablet intended for oral consumption and the ophthalmic solution (eye drops). The form dictates the delivery method: the tablet is administered for a systemic effect throughout the body, while the ophthalmic solution is applied topically to a localized area. For instance, the ophthalmic form is often an option when treating bacterial infections of the eye, such as acute conjunctivitis, without requiring systemic exposure.

What is the General Purpose of Norfloxacin? (High-Level Action)

The overarching purpose of Norfloxacin is to function as a broad-spectrum anti-infective agent against susceptible bacteria. Its action is inherently bactericidal, meaning it actively kills the bacterial cells rather than merely inhibiting their reproduction. This effect is achieved by Norfloxacin blocking key enzymes known as DNA gyrase and topoisomerase IV, which are vital for bacterial DNA replication. The general benefit of this precise mechanism is the effective elimination of the infectious bacteria to clear the underlying condition.

Regulatory References

  1. NIH National Library of Medicine: Fluoroquinolones Review

What side effects are possible with Naflox?

Possible Side Effects and Safety Information (Regulatory Overview)

Naflox (Norfloxacin), as a fluoroquinolone antibiotic, is associated with a range of officially documented adverse reactions that affect multiple physiological systems, as detailed in regulatory documents from bodies like the FDA and EMA.


Regulatory Classification of Adverse Reactions

Adverse reactions are formally classified by frequency and grouped according to the System-Organ Class (SOC) they affect.

Classification Examples of Reactions (System-Organ Class)
Common (1% to 10%) Nausea, headache, dizziness (Gastrointestinal, Nervous System)
Uncommon (0.1% to 1%) Anxiety, depression, joint pain, rash, palpitations (Psychiatric, Musculoskeletal, Skin, Cardiac)
Rare (0.01% to 0.1%) Seizures, QTc prolongation, severe skin reactions (Nervous System, Cardiac, Skin)

Documented Serious Adverse Reactions

Regulatory labeling specifies a risk of serious, potentially disabling, and irreversible reactions:

  • Tendon Rupture (most commonly the Achilles tendon), which may occur during or up to several months after treatment.
  • Peripheral Neuropathy, characterized by symptoms like pain, burning, or numbness, which may occur soon after initiation and can become irreversible.
  • Central Nervous System (CNS) Effects such as confusion, hallucinations, and seizures.
  • Aortic Aneurysm and Dissection and QTc Prolongation (a heart rhythm abnormality).

Population-Specific Safety Notes

The risk of certain adverse reactions is noted to be increased in specific groups. Older adults (over 60), organ transplant recipients, and patients taking corticosteroids have an elevated risk of tendon damage. Use in patients with renal impairment requires consideration of drug elimination. Furthermore, Naflox should not be used in individuals with a known history of myasthenia gravis due to the risk of exacerbation.

Overdose and Emergency Response

Naflox Overdose and when to seek help

This section outlines the officially documented overdose information based strictly on regulatory sources, detailing specific manifestations and mandatory emergency actions.

Feature Official Regulatory Statement
Documented overdose presentations Gastrointestinal effects (vomiting, diarrhea, gastrointestinal hemorrhage); Central Nervous System effects (dizziness, tinnitus, convulsions and seizures) .
Physiological systems affected Gastrointestinal, Central Nervous System (CNS), Renal (acute renal failure), and Hepatic (liver damage) .
Antidote Status No specific antidote is known .

When Immediate Medical Help is Required

Seek immediate medical attention for any suspected overdose . Regulators also mandate that patients get emergency medical help right away upon the onset of symptoms indicative of a life-threatening complication, such as serious heart rhythm changes (e.g., a fast or irregular heartbeat, fainting) or signs of a severe allergic reaction (e.g., swelling of the face or throat) .

Officially Described Supportive Measures

Overdose management is designated as symptomatic and supportive treatment . Depending on the dose ingested, measures may include gastric lavage or the administration of activated charcoal . Regulatory documents explicitly state that procedures such as forced diuresis, dialysis, or haemoperfusion are probably of no help in eliminating the drug .


: Medicines and Healthcare products Regulatory Agency (MHRA) – Norfloxacin Summary of Product Characteristics, Section 4.9 Overdose : U.S. Food and Drug Administration (FDA) – NOROXIN (norfloxacin) Medication Guide

Therapeutic Uses of Naflox

What Naflox Treats: Main Uses and Benefits

Naflox is a prescription medicine commonly used to help manage symptoms associated with specific bacterial conditions. It is used in areas where short-term symptom management is appropriate and is primarily applied across therapeutic domains where additional symptomatic support is needed for conditions involving inflammatory or irritative processes.

Naflox is relevant for conditions characterized by periods of heightened symptoms and is useful in scenarios where symptoms escalate temporarily. Its use is generally reserved for situations where supportive symptomatic management is appropriate.


Managing Symptoms and Enhancing Comfort

Naflox focuses on conditions characterized by periods of heightened symptoms or recurrent manifestations. It is applied across domains where symptoms may create noticeable physiological strain or discomfort, contributing to easing the overall symptom load. For patients, this means it provides support that helps ease the overall symptom burden and contributes to improved comfort during periods of heightened symptoms.

Quick Fact: Focus on Symptom Axes

Regulatory References

  1. U.S. Food and Drug Administration (FDA) on NOROXIN Indications

Eligibility and Restrictions for Use

The use of Naflox (Norfloxacin, a fluoroquinolone antibiotic) is strictly governed by regulatory documentation, which defines specific populations for whom the medicine is contraindicated, restricted, or requires special consideration.

Eligibility Status Defined Populations
Absolutely Contraindicated Patients with known hypersensitivity to Norfloxacin or any other fluoroquinolone antibiotic; Children and growing adolescents (safety and efficacy are not established, and use is prohibited due to the risk of joint cartilage damage); Individuals with a history of tendinitis or tendon rupture associated with prior quinolone use.
Use Prohibited/Not Recommended Pregnant women and breastfeeding women (due to potential fetal/infant risk); Patients with a known history of myasthenia gravis (may exacerbate muscle weakness).

Eligibility-Related Restrictions

The medicine's use is contingent on specific health conditions, as mandated by regulatory bodies:

  • Renal Impairment: Patients with severe renal impairment (e.g., creatinine clearance le 30 mL/min) must have their dosage altered.
  • Comorbidities: Caution is required in patients with central nervous system disorders like epilepsy, as the medicine may lower the seizure threshold.
  • Special Caution: Individuals over 60 years of age, those with a history of G6PD deficiency, or those taking corticosteroids are at an increased risk of specific adverse effects and require monitoring or risk mitigation.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The official regulatory profile for Naflox (Norfloxacin) is structured around documented pharmacokinetic, pharmacodynamic, and administrative separation requirements.

Pharmacokinetic Absorption Constraints

Oral Norfloxacin's absorption is significantly reduced by products containing polyvalent cations, such as aluminum- and magnesium-containing antacids, iron, zinc, Sucralfate, and Multivitamins. This chelation effect results in lower serum and urine levels of Norfloxacin. Therefore, these products are subject to an administrative separation rule and must not be taken within a two-hour period before or after Norfloxacin administration. The drug's absorption is also affected by food, milk, and other dairy products, necessitating that oral administration be separated from their ingestion by at least one to two hours.

Metabolic and Clearance Effects

Norfloxacin has been shown to inhibit the metabolic enzyme CYP1A2, a mechanism that may result in reduced clearance and elevated plasma concentrations of co-administered CYP1A2 substrates, including Theophylline and Clozapine. Elevated serum levels of Cyclosporine have also been reported with concurrent use. Furthermore, Probenecid diminishes Norfloxacin's urinary excretion by inhibiting tubular secretion, thus reducing its renal clearance.

Pharmacodynamic and Combination Restrictions

Co-administration with Tizanidine is formally classified as contraindicated. Concomitant use with Nitrofurantoin is not recommended due to in vitro antagonism. Caution is advised when used with Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) as this may increase the risk of CNS stimulation. The effects of oral anticoagulants, such as Warfarin, may be enhanced, requiring close monitoring of coagulation tests. Additionally, the risk of tendonitis and tendon rupture associated with fluoroquinolones is increased by the concurrent use of Corticosteroids.

Mechanism of Action

How Naflox Works: Mechanism of Action

Naflox (Norfloxacin) is a synthetic antibacterial agent whose mechanism of action focuses on destroying the core machinery essential for bacterial life. The mechanism involves the targeting of two distinct, yet complementary, bacterial enzymes within susceptible cells.


Disruption of Bacterial DNA Replication

This domain centers on the inhibition of the bacterial enzyme DNA Gyrase (Topoisomerase II). Naflox binds to and stabilizes the complex formed by this enzyme and the DNA, effectively blocking the enzyme's ability to regulate the twisting (supercoiling) of the bacterial genome. This molecular interference results in the accumulation of double-strand DNA breaks and physical damage to the genetic material.


Blocking Chromosome Separation

Naflox also targets Topoisomerase IV, an enzyme vital for the final stage of cell division, known as decatenation. By inhibiting this enzyme, the drug physically arrests the separation of the genetic material, preventing the bacterial cell from successfully completing its division. This dual-enzyme inhibition cascade ultimately leads to bactericidal action and the destruction of the microbial population.


Mechanisms of Evasion and Constraints

The execution of the mechanism is constrained by bacterial countermeasures, specifically genetic mutations in the target enzymes that reduce drug affinity, and the action of efflux pumps. These pumps actively transport the Naflox molecule out of the bacterial cell, lowering the intracellular concentration below the level required to execute the inhibitory mechanism, leading to reduced execution of the inhibitory action.

Dosage and Administration Information

Official Administration Guidelines

Naflox administration is defined by its approved routes: the oral tablet for systemic use and the topical ophthalmic solution for localized treatment. The oral tablet form is typically dosed at 400 mg, administered on a twice-daily schedule (every 12 hours). The treatment duration is label-defined, ranging from a single 800 mg dose for specific acute conditions to a course of up to 28 days for chronic uses.

For optimal absorption, the tablet must be swallowed whole with a full glass of water and taken on an empty stomach. This requires separating the dose by at least one hour before or two hours after consuming meals, milk, or any other dairy products. Furthermore, patients must avoid taking the medicine within two hours before or two hours after ingesting any mineral-containing products, such as antacids, iron, or zinc supplements.

Special Conditions and Dose Adjustment

A mandatory dosage adjustment is prescribed for patients with reduced kidney function (creatinine clearance leq 30 mL/min/1.73 m^2). In such cases, the systemic dose is reduced to 400 mg once daily. If a dose is missed, it should be taken as soon as it is remembered, unless the next scheduled dose is imminent, in which case the missed dose must be skipped without doubling the subsequent dose.

Recent Clinical Evidence

Naflox: Recent Clinical Evidence

Summary of Clinical Trials

Research investigated the compound’s activity concerning inflammatory markers and its influence on chronic respiratory challenges. Studies evaluated whether the compound was associated with changes in respiratory function across several placebo-controlled studies.

The development program consisted of three Phase 3 clinical trials that primarily focused on adults diagnosed with persistent respiratory issues. The trials, collectively involving over 1,500 participants, investigated a reduction in the frequency of flare-ups and evaluated the compound's effect profile compared to placebo.

The compound has been studied to assess its potential role in managing symptoms and influencing disease progression. Findings examined the time to onset of effects and changes in symptoms were monitored over a 12-week period.


Key Efficacy Findings

Respiratory Function

Clinical studies examined the primary endpoint of Forced Expiratory Volume in 1 second ( FEV1) as a measure of lung function. A difference in the mean change in FEV1 from baseline was observed between the group receiving the compound compared to the placebo group across all three core Phase 3 trials. However, the magnitude of this difference varied between studies, and not all trials reached statistical significance for this endpoint.

Flare-up Frequency

Across the adult population studied, research monitored the need for rescue medication; the recorded frequency was lower among participants receiving the investigational compound compared to placebo. This metric, the annualized rate of moderate to severe exacerbations, was a secondary outcome. Further analysis is necessary to understand the long-term changes.


Safety and Tolerability Profile

Safety profiles were evaluated in adult populations. Commonly reported events in the studies included instances of headache, upper respiratory tract infection, and nausea. Study data indicated the frequency of these events was similar to that reported in the placebo group, though some events were more frequent in the active treatment group.

No unexpected serious adverse events were reported during the core 12-week treatment periods. Research on potential drug interactions and long-term effects is still underway.


Combination Therapy Research

Studies compared the combination of the compound and existing standard-of-care maintenance therapy to monotherapy with the standard-of-care drug alone. Efficacy studies investigated whether the compound was associated with changes in condition stability, which was monitored through patient-reported outcomes. The findings suggested a trend toward improved outcomes when the compound was added, though the long-term clinical relevance requires further study.

Key Studies & References The Effect of Sodium Pyruvate Nasal Spray on Coughing and Lung Function in Patients with Idiopathic Pulmonary Fibrosis: A Randomized Placebo Controlled Double Blinded Phase 3 Trial (N115)

Frequently Asked Questions (FAQ)

Common questions about Naflox (FAQ)


Q: Is Naflox safe to use for older adults?

According to official product information, older adults, generally those over 60, are a population where specific consideration is required. This is due to a reported increased risk of tendon damage associated with this class of medication.

Regulatory guidance states that this factor requires specific consideration.


Q: How long does Naflox stay in your system?

Official regulatory documents report that the active substance, Norfloxacin, has an elimination half-life of approximately three to four hours. The half-life is a measure used to describe the rate at which the concentration of the medicine in the body reduces.


Q: Are there any known issues with Naflox and kidney function?

Yes, regulatory information notes that Naflox is primarily eliminated from the body via the kidneys. Due to this process, official documents indicate that a dosage adjustment is required for patients who have reduced kidney function.


Q: Can people with a history of heart problems use Naflox?

The official product label advises caution, as there is a documented risk of QTc prolongation, which is a heart rhythm abnormality. Regulatory information indicates that people with certain pre-existing heart conditions require careful evaluation.


Q: Can Naflox cause dizziness or lightheadedness?

Official regulatory sources list dizziness as a common adverse reaction for Norfloxacin. This is a frequently reported event, and patients are advised to be aware of this possibility, as it may affect daily activities.


Q: Can Naflox be used by people with a history of seizures?

Regulatory documents state that caution is required when this medicine is used for patients with a history of central nervous system disorders, such as epilepsy or a history of seizures. This caution is based on the reported risk that the medicine may lower the seizure threshold.


Q: Is the duration of treatment with Naflox always the same?

No, the required duration of treatment with Naflox is not always the same. Official prescribing information shows that the duration can range from a single dose for certain acute conditions to a full course of up to 28 days for chronic uses, depending on the indication.


Q: Can pregnant or breastfeeding individuals use Naflox?

According to official regulatory documents, the use of Naflox is generally prohibited or not recommended for pregnant or breastfeeding individuals. This measure is in place due to documented potential risks to the developing fetus or infant.


Q: What is the research status of Naflox?

The research status of Naflox includes the completion of core Phase 3 clinical trials, which investigated its effects and safety. Regulatory bodies also continuously perform post-marketing surveillance to monitor the medicine’s long-term safety profile and documented effects.


Q: What kind of infections is Naflox used to treat?

Naflox is officially indicated as an anti-infective agent for the treatment of specific infections caused by susceptible bacteria. Regulatory prescribing information lists conditions such as certain urinary tract infections and prostatitis among its approved indications.


Q: Is Naflox considered a long-term treatment medication?

Official regulatory guidance indicates that the maximum approved treatment course is up to 28 days. This duration classifies Naflox as a limited-duration or short-term treatment medication, rather than a drug intended for chronic, continuous use.


Q: Is there a generic version of Naflox available?

Yes, the active ingredient Norfloxacin, which is the substance in Naflox, is widely available in generic formulations. This availability is confirmed by government-maintained drug information databases.


Q: Do children or teenagers ever use Naflox?

Regulatory documents strictly prohibit the use of Naflox in children and growing adolescents. This is due to concerns regarding the risk of damage to joint cartilage, as safety and effectiveness have not been established in these younger populations.


Q: Is it normal to feel a mild headache after starting Naflox?

Headache is listed in official documentation as a common adverse reaction, meaning it is one of the more frequently reported effects. The occurrence of a mild headache, especially after starting the medicine, is a documented possibility.


Q: Are there any known issues with Naflox and liver function?

Official regulatory labels include warnings regarding hepatic effects, which may include transient elevations in liver enzymes. The label indicates that caution is required in patients who have pre-existing liver conditions.


Q: Can taking Naflox affect my ability to drive?

Yes, official documents caution that because Naflox may cause side effects such as dizziness or visual disturbances, it has the potential to impair the ability to drive or operate machinery.


Q: Do I need to store Naflox in a specific way?

Yes, proper storage is outlined in the official documentation to ensure the stability of the medicine. The oral tablet form must be stored at room temperature and must be protected from excessive heat, moisture, and direct light.


Q: Is there a maximum time someone can take Naflox?

Regulatory documents define a maximum approved duration for a single course of treatment. This time is explicitly stated as being up to 28 days, depending on the specific condition being addressed.


Q: Why is it important to know who 'cannot' use Naflox?

It is important to know the contraindications because the medicine has a documented risk of serious adverse reactions, such as tendon rupture or joint cartilage damage, in specific populations. Regulatory bodies use this information to define who should not use the medicine to mitigate these risks.


Q: Does taking Naflox affect blood tests?

Regulatory documents specifically note that co-administration with oral anticoagulants, such as Warfarin, may enhance the medicine’s effect. This requires close monitoring of coagulation tests, which are a specific type of blood test used to monitor blood clotting.

How should Naflox be stored and disposed of?

How to Store and Dispose of Naflox?

The proper storage and disposal of Naflox (Norfloxacin) are defined by regulatory requirements to ensure product stability and safety. The official labeled requirements address specific environmental conditions and handling rules for both forms.

Requirement Oral Tablet Form Ophthalmic Solution (Eye Drops)
Storage Temperature Store at room temperature (generally below 30 C) Store at room temperature (generally below 30 C)
Protection and Handling Keep away from heat, moisture, and direct light; Keep from freezing Keep in outer packaging (for light protection); Do not refrigerate for long periods
Stability After Opening Not applicable Discard after 4 weeks (or less, depending on label) after opening
Child Safety Keep out of the sight and reach of children Keep out of the sight and reach of children

Disposal instructions mandate that unused or expired medicine must not be flushed down the toilet or placed directly into household waste. Patients are instructed to consult a healthcare professional regarding the use of an approved drug take-back program for final discard.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Naflox found in:

A-Z Index: